Skip to main content

Table 1 Patient characteristics

From: Influence of Mitroflow bioprosthesis structural valve deterioration on cardiac morbidity

 

Total

Group 1

Group 2

Group 3

P-value

n = 211

n = 53

n = 59

n = 99

 

Age at operation (years)

76.8 ± 5.3

76.9 ± 5.7

76.9 ± 5.3

76.8 ± 5.2

0.992

Women

155 (73.5)

42 (79.3)

42 (71.2)

71 (71.7)

0.543

BSA (m2)

1.73 ± 0.19

1.72 ± 0.16

1.76 ± 0.21

1.72 ± 0.19

0.217

EuroScore II

1.6 ± 1.3

1.6 ± 1.1

1.6 ± 1.1

1.6 ± 1.6

0.999

NYHA

2.5 ± 0.7

2.5 ± 0.8

2.6 ± 0.8

2.4 ± 0.7

0.552

CCS

1.2 ± 1.3

1.2 ± 1.3

1.4 ± 1.2

1 ± 1.3

0.141

Blood pressure

 Systolic (mmHg)

147 ± 27

150 ± 28

144 ± 25

147 ± 27

0.574

 Diastolic (mmHg)

79 ± 16

80 ± 20

77 ± 13

79 ± 15

0.730

eGFR (mL/min/1.73 m2)

50 ± 24

46 ± 18

52 ± 25

51 ± 25

0.574

50

53 (44.9)

11 (39.3)

19 (47.5)

23 (46)

0.783

 < 50

65 (55.1)

17 (60.7)

21 (52.5)

27 (54)

0.783

Smoker

    

0.503

 Never

68 (32.5)

21 (40.4)

17 (28.8)

30 (30.6)

 

 Active

95 (45.5)

19 (36.5)

31 (52.5)

45 (45.9)

 

 Quit

46 (22)

12 (23.1)

11 (18.6)

23 (23.5)

 

Diabetes

26 (12.4)

7 (13.5)

6 (10.2)

13 (13.1)

0.830

Hypertension

115 (55)

33 (63.5)

34 (58.6)

48 (48.5)

0.173

Ischaemic heart disease

108 (51.9)

31 (59.6)

37 (63.8)*

40 (40.8)*

< 0.001

Previous PCI

9 (4.3)

4 (7.6)

3 (5.3)

2 (2.0)

0.261

Previous CABG

7 (3.4)

1 (1.9)

4 (6.8)

2 (2.1)

0.224

Extracardiac arteriopathy

23 (10.9)

7 (13.2)

10 (17.0)

6 (6.1)

0.086

Atrial fibrillation

41 (19.8)

15 (28.3)

12 (20.7)

14 (14.6)

0.13

Apoplexia cerebri

22 (10.6)

7 (13.2)

6 (10.3)

9 (9.4)

0.765

COPD

37 (17.9)

6 (11.5)

11 (18.6)

20 (20.8)

0.365

Pre-operative echo

 EF (%)

54 ± 13

53 ± 13

54 ± 12

55 ± 13

0.782

 Aorta area (cm2)

0.68 ± 0.2

0.68 ± 0.2

0.68 ± 0.2

0.68 ± 0.2

0.968

 Aorta CW max (mmHg)

74 ± 28

73 ± 28

70 ± 23

76 ± 32

0.486

  1. Values are mean ± standard deviation or as number and percent
  2. BSA Body surface area, CABG Coronary artery bypass graft, CCS Canadian Cardiovascular Society, COPD Chronic obstructive pulmonary disease, EF Ejection fraction, eGFR Estimated glomerular filtration rate, PCI Percutaneous coronary intervention, NYHA New York Heart Association
  3. *Significantly different, p < 0.05